European Industry Leaders From Energy, Mobility & Sustainability Join Energy Impact Partners Global Innovation Platform
16.7.2020 17:00:00 EEST | Business Wire | Press release
Energy Impact Partners (EIP), the global investment platform leading the transition to a sustainable energy future, has announced the formation of a European Coalition to advance new technologies and tackle climate change. EIP works closely with its investors -- more than 25 of the largest, most innovative, and environmentally conscious energy and industrial companies as well as climate-investors -- to develop cutting-edge solutions across four continents through a unique collaborative model. The EIP network collaborates by sharing insights, investing in innovative and transformative businesses, and then amplifying entrepreneurs' growth through dedicated partnerships.
“Our proven model is based on collaboration, learning, and sharing -- and it can only thrive with the right partners. We are thrilled to see some of the most innovative European players and AGL, the leading utility in Australia, join our mission as founding members.”
- Matthias Dill, CEO & Managing Director Europe for Energy Impact Partners
“Energy Impact Partners’ unique set up with strong focus in collaboration, partnerships and creating valuable insights is an efficient way to strengthen Fortum’s presence in global energy innovation ecosystem. As a partner, Fortum will gain early access to new business models and solutions in both European and US markets. The aim is to be in the frontlines in finding, piloting and scaling the innovations with potential to change the energy sector as we know it.”
- Arun Aggarwal, SVP of Fortum’s Business Technology unit
The newly formed European Coalition complements EIP’s proven North American model with investors from four continents and provide unparalleled insights for its partners and global market access for its portfolio. The coalition encompasses over 25 industrials with revenues exceeding the combined sales of Amazon, Facebook and Google and access to more than 200 million households.
“We look forward to learning, collaborating and defining the energy landscape of the future. Innovation is a global business and by collaborating we can tackle future challenges more effectively.”
- Urban Keussen, CTO of EWE and Chairman of the European Coalition
“To halt climate change, we need to make an impact now. By bringing together industry, capital and visionaries we have the best chance to succeed. We look forward to working with EIP in Norway and beyond.”
- Siri Kalvig, CEO of Nysno Climate Investments and Chair of EIP’s ESG Committee
"Climate related technologies are progressing at an impressive pace, both in Europe and globally. By partnering with EIP we get the chance to both contribute to the development and learn from the achievements of other interesting companies. The investment strengthens our position towards new energy related markets and ideas and helps us stay in the forefront in terms of smarter and more climate friendly energy solutions."
- Ståle Gjersvold, CEO at TrønderEnergi
"AGL is happy to extend our valued partnership with EIP. We have been impressed with the EIP model and we’re confident it will be successful in the European markets.”
- Simon Moorfield, Executive General Manager at AGL
About Energy Impact Partners
Energy Impact Partners (EIP) is a global investment platform leading the transition to a sustainable energy future. EIP brings together entrepreneurs and the world's most forward-looking energy and industrial companies to advance innovation. With over $1.5 billion in assets under management, EIP invests globally across venture, growth, credit and infrastructure – and has a team of more than 45 professionals based in its offices in New York, San Francisco, Palm Beach, London, Cologne and soon Oslo. For more information on EIP, please visit www.energyimpactpartners.com. EIP’s network has over 25 partners including Southern Company, Xcel Energy, Fortis, Duke Energy, Tennessee Valley Authority Asset Retirement Trust, Emera, APS, NYSNO, TronderEnergi, EWE, Enterprise Holdings, Fortum, Evergy, OG&E, Ameren, TC Energy, Alliant Energy, Avista, National Grid, PTT, TEPCO, AGL, 1898&co and MGE.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005643/en/
Contact information
EU Press
Antonella Scimemi
Burlington
antonella@burlington.cc
+44 (0)7530 815 018
U.S. Press
Tori McDonnell
Silverline Communications
tori@teamsilverline.com
01-703-338-2362
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom